[go: up one dir, main page]

WO2018071910A3 - Anticorps anti-il1-rap - Google Patents

Anticorps anti-il1-rap Download PDF

Info

Publication number
WO2018071910A3
WO2018071910A3 PCT/US2017/056808 US2017056808W WO2018071910A3 WO 2018071910 A3 WO2018071910 A3 WO 2018071910A3 US 2017056808 W US2017056808 W US 2017056808W WO 2018071910 A3 WO2018071910 A3 WO 2018071910A3
Authority
WO
WIPO (PCT)
Prior art keywords
rap antibodies
rap
antibodies
antibodies specific
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/056808
Other languages
English (en)
Other versions
WO2018071910A2 (fr
Inventor
Ying Ping JIANG
Jagath R. Junutula
Leonard G. Presta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellerant Therapeutics Inc
Original Assignee
Cellerant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/055994 external-priority patent/WO2018071455A1/fr
Priority to CA3084459A priority Critical patent/CA3084459A1/fr
Priority to EP17860212.4A priority patent/EP3526247A4/fr
Priority to JP2019520368A priority patent/JP7032394B2/ja
Priority to AU2017343784A priority patent/AU2017343784A1/en
Priority to CN201780075197.7A priority patent/CN110036028B/zh
Application filed by Cellerant Therapeutics Inc filed Critical Cellerant Therapeutics Inc
Priority to US16/342,176 priority patent/US11359025B2/en
Publication of WO2018071910A2 publication Critical patent/WO2018071910A2/fr
Publication of WO2018071910A3 publication Critical patent/WO2018071910A3/fr
Anticipated expiration legal-status Critical
Priority to JP2022026299A priority patent/JP7235904B2/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des anticorps spécifiques contre IL1-RAP.
PCT/US2017/056808 2016-10-16 2017-10-16 Anticorps anti-il1-rap Ceased WO2018071910A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US16/342,176 US11359025B2 (en) 2016-10-16 2017-10-16 Anti-IL1-RAP antibodies
EP17860212.4A EP3526247A4 (fr) 2016-10-16 2017-10-16 Anticorps anti-il1-rap
JP2019520368A JP7032394B2 (ja) 2016-10-16 2017-10-16 抗ｉｌ１－ｒａｐ抗体
AU2017343784A AU2017343784A1 (en) 2016-10-16 2017-10-16 Anti-IL1-RAP antibodies
CN201780075197.7A CN110036028B (zh) 2016-10-16 2017-10-16 抗il1-rap抗体
CA3084459A CA3084459A1 (fr) 2016-10-16 2017-10-16 Anticorps anti-il1-rap
JP2022026299A JP7235904B2 (ja) 2016-10-16 2022-02-24 抗ｉｌ１－ｒａｐ抗体

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662408807P 2016-10-16 2016-10-16
US62/408,807 2016-10-16
US201662425970P 2016-11-23 2016-11-23
US62/425,970 2016-11-23
PCT/US2017/055994 WO2018071455A1 (fr) 2016-10-10 2017-10-10 Dimères d'isoquinolidinobenzodiazépine (iqb)-1(chlorométhyl)-2,3-dihydro-1h-benzo[e]indole (cbi)
USPCT/US2017/055994 2017-10-10

Publications (2)

Publication Number Publication Date
WO2018071910A2 WO2018071910A2 (fr) 2018-04-19
WO2018071910A3 true WO2018071910A3 (fr) 2018-05-17

Family

ID=61906090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/056808 Ceased WO2018071910A2 (fr) 2016-10-16 2017-10-16 Anticorps anti-il1-rap

Country Status (1)

Country Link
WO (1) WO2018071910A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
EP3508498A1 (fr) 2011-01-19 2019-07-10 Cantargia AB Nouveaux agents et leurs utilisations
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
AU2017343565A1 (en) 2016-10-10 2019-05-30 Cellerant Therapeutics, Inc. Isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers
WO2020035577A1 (fr) 2018-08-16 2020-02-20 Cantargia Ab Compositions d'anticorps anti-il1rap
JP2022537411A (ja) * 2019-06-21 2022-08-25 シングル セル テクノロジー， インコーポレイテッド 抗ｔｉｍ－３抗体
BR112021025476A2 (pt) * 2019-06-26 2022-10-11 Glaxosmithkline Ip Dev Ltd Proteínas de ligação à il1rap
JP2023541627A (ja) 2020-09-14 2023-10-03 イシュノス サイエンシズ ソシエテ アノニム Ｉｌ１ｒａｐに結合する抗体及びその使用
JP2024505674A (ja) * 2021-02-05 2024-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ１ｒａｐ抗体
IL308602A (en) 2021-05-21 2024-01-01 Leo Pharma As Anti-IL-1 receptor associated protein antibodies
CA3226673A1 (fr) * 2021-07-21 2023-01-21 Stelexis Therapeutics, Llc Anticorps il1rap et utilisations connexes
WO2024047558A2 (fr) * 2022-08-31 2024-03-07 Immuneel Therapeutics Private Limited Protéines de liaison à l'antigène et récepteurs antigéniques chimériques spécifiques pour le domaine 9 de cd307e humain

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020058247A1 (en) * 2000-04-21 2002-05-16 Matti Sallberg Synthetic peptides that bind to the hepatitis B virus core and e antigens
US20030007976A1 (en) * 1997-12-23 2003-01-09 Watson James D. Methods and compounds for the treatment of immunologically-mediated skin disorders
WO2010036959A2 (fr) * 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Anticorps anti-pd-1, pd-l1, et pd-l2 humains et leurs utilisations
US20100272731A1 (en) * 2007-02-23 2010-10-28 Schering Corporation Engineered anti-il-23p19 antibodies
US20150315279A1 (en) * 2012-12-21 2015-11-05 Cellerant Therapeutics, Inc. Antibodies that bind membrane-bound il1rap

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030007976A1 (en) * 1997-12-23 2003-01-09 Watson James D. Methods and compounds for the treatment of immunologically-mediated skin disorders
US20020058247A1 (en) * 2000-04-21 2002-05-16 Matti Sallberg Synthetic peptides that bind to the hepatitis B virus core and e antigens
US20100272731A1 (en) * 2007-02-23 2010-10-28 Schering Corporation Engineered anti-il-23p19 antibodies
WO2010036959A2 (fr) * 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Anticorps anti-pd-1, pd-l1, et pd-l2 humains et leurs utilisations
US20150315279A1 (en) * 2012-12-21 2015-11-05 Cellerant Therapeutics, Inc. Antibodies that bind membrane-bound il1rap

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProtKB 19 October 2011 (2011-10-19), ANONYMOUS, XP055600623, retrieved from UNIPROT Database accession no. F8X0L8 *
DATABASE UniProtKB 29 April 2015 (2015-04-29), ANONYMOUS, XP055600618, retrieved from UNIPROT Database accession no. A0A0C9YH80 *
DATABASE UniProtKB 6 February 2013 (2013-02-06), ANONYMOUS, XP055600626, retrieved from UNIPROT Database accession no. K7U5T0 *

Also Published As

Publication number Publication date
WO2018071910A2 (fr) 2018-04-19

Similar Documents

Publication Publication Date Title
WO2018071910A3 (fr) Anticorps anti-il1-rap
EP3765522A4 (fr) Anticorps anti-claudine 18.2
EP3589313A4 (fr) Anticorps anti-tigit
EP3606961B8 (fr) Anticorps anti-garp-tgf-beta
EP3522922A4 (fr) Nouveaux anticorps anti-ctla4
EP3492591A4 (fr) Anticorps anti-b7-h4
WO2016166296A3 (fr) Anticorps humanisés anti-axl
EP3634997B8 (fr) Anticorps anti hsa
AU2019361253A1 (en) Anti-synuclein antibodies
EP3766898A4 (fr) Anticorps reconnaissant cadm1 v9
EP3604517A4 (fr) Anticorps anti-apoa1
EP3674324A4 (fr) Anticorps anti-podoplanine
HK40103775A (zh) 抗hla-dq2.5 抗体
HK40094440A (zh) 抗聚泛素多特异性抗体
HK40060479A (zh) 抗btla抗体
HK40054305A (en) Anti-klrg1 antibodies
HK40046591A (en) Anti-tigit antibodies
HK40033943A (en) Novel anti-cd3epsilon antibodies
HK40041749A (en) Anti-il36r antibodies
HK40035184A (en) Anti-transthyretin antibodies
HK40042692A (en) Il-11ra antibodies
HK40032571A (en) Anti-il1rap antibodies
HK40046106A (zh) 抗体
HK40017166A (en) Anti-trkb antibodies
HK40021303A (en) Garp-tgf-beta antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17860212

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2019520368

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017860212

Country of ref document: EP

Effective date: 20190516

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17860212

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2017343784

Country of ref document: AU

Date of ref document: 20171016

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3084459

Country of ref document: CA